Catalyst Pharmaceuticals (CPRX) Other Accumulated Expenses (2011 - 2026)
Catalyst Pharmaceuticals posted quarterly Other Accumulated Expenses of $745000.0 for Q1 2026, down 66.52% year-on-year from $2.2 million in Q1 2025, and down 11.31% on a QoQ basis from $840000.0 in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 11 years of Other Accumulated Expenses data on file, last reported at $745000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses fell 66.52% year-over-year to $745000.0; the trailing twelve-month figure through Mar 2026 stood at $745000.0 (down 66.52% YoY), and the FY2025 full-year result was $840000.0, up 101.44% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $745000.0, down from $840000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $2.2 million in Q1 2025 and bottomed at $372000.0 in Q2 2024.
- The 4-year median for Other Accumulated Expenses is $745000.0 (2026), against an average of $789111.1.
- The widest annual swing landed in 2025, when Other Accumulated Expenses soared 101.44%; it then plunged 66.52% in 2026.
- A 4-year view of Other Accumulated Expenses shows it stood at $465000.0 in 2023, then declined by 10.32% to $417000.0 in 2024, then jumped by 101.44% to $840000.0 in 2025, then dropped by 11.31% to $745000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $745000.0 (Q1 2026), $840000.0 (Q4 2025), and $842000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 745,000.00 |
| Dec 31, 2025 | 840,000.00 |
| Sep 30, 2025 | 842,000.00 |
| Jun 30, 2025 | 747,000.00 |
| Mar 31, 2025 | 2.23 Mn |
| Dec 31, 2024 | 417,000.00 |
| Sep 30, 2024 | 449,000.00 |
| Jun 30, 2024 | 372,000.00 |
| Dec 31, 2023 | 465,000.00 |
| Dec 31, 2018 | 66,436.00 |
| Sep 30, 2018 | 38,958.00 |
| Jun 30, 2018 | 4,738.00 |
| Mar 31, 2018 | 19,136.00 |
| Dec 31, 2017 | 24,035.00 |
| Sep 30, 2017 | 12,559.00 |
| Jun 30, 2017 | 2,839.00 |
| Mar 31, 2017 | 7,723.00 |
| Dec 31, 2015 | 17,642.00 |
| Sep 30, 2015 | 21,614.00 |
| Jun 30, 2015 | 77,961.00 |
| Mar 31, 2015 | 41,057.00 |
| Dec 31, 2014 | 3.50 Mn |
| Sep 30, 2014 | 8,531.00 |
| Jun 30, 2014 | 3,213.00 |
| Mar 31, 2014 | 4,397.00 |
| Dec 31, 2013 | 5,546.00 |
| Sep 30, 2013 | 2,930.00 |
| Jun 30, 2013 | 3,364.00 |
| Mar 31, 2013 | 10,839.00 |
| Dec 31, 2012 | 10,666.00 |
| Sep 30, 2012 | 5,823.00 |
| Jun 30, 2012 | 9,407.00 |
| Dec 31, 2011 | 14,437.00 |